Abstracts tagged "Biologicals"

Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 1469 • ACR Convergence 2024
Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
María Rocío González Molina¹, C Marín Huertas², B Joven-Ibáñez³, L de Prado⁴, Lourdes Mateo⁵, M Llanes Gómez⁶, A Hernández del Río⁷, EA Blanco-Morales⁸, J Malavé Calzada⁹, Meritxell Sallés Lizarzaburu¹⁰, Inmaculada Ros-Vilamajó¹¹, Martina Steiner¹², EVELIN CERVANTES PEREZ¹³, Vanesa Hernández-Hernández¹⁴, S Castro Oreiro¹⁵, ANA URRUTICOECHEA¹⁶, L Orpinell Palacio¹⁷, J Campos Esteban¹⁸, Raúl Veroz González¹⁹, O Camacho Alcázar²⁰, MP Moreno-Gil²¹, A Aragón Díez²², MJ Moreno-Ramos²³, FJ Maceiras Pan²⁴, S Díaz-Castroverde²⁵, Santiago Muñoz Fernández²⁶, JA Pinto Tasende²⁷ and J Ramírez García²⁸, ¹Hospital Reina Sofía, Murcia, Murcia, Spain, ²Hospital Infanta Leonor, Madrid, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ⁴Hospital de Mollet, Mollet del Vallès, Barcelona, Catalonia, Spain, ⁵H Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain, ⁷Hospital Naval, Ferrol, A Coruña, Galicia, Spain, ⁸Hospital Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Hospital Virgen del Puerto, Plasencia, Cáceres, Extremadura, Spain, ¹⁰Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ¹¹Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹²Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ¹³Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ¹⁴Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁵Hospital Sant Joan XXIII, Tarragona, Catalonia, Spain, ¹⁶Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ¹⁷Hospital Sagrat Cor, Barcelona, Spain, ¹⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Hospital Mérida, Badajoz, Spain, ²⁰Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Catalonia, Spain, ²¹Hospital San Pedro de Alcántara, Cáceres, Extremadura, Spain, ²²Hospital Universitario de Getafe, Getafe, Madrid, Madrid, Spain, ²³Hospital Virgen de Arrixaca, Murcia, Murcia, Spain, ²⁴Hospital de Meixoeiro, Pontevedra, Galicia, Spain, ²⁵Johnson&Johnson Innovative Medicine, Madrid, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, ²⁷Complejo Hospitalario Universitario, A Coruña, Spain, ²⁸Hospital Clínic, Barcelona, Spain
Background/Purpose: PsA is a complex inflammatory condition affecting both the skin and musculoskeletal system. Clinical guidelines recommend biological therapies after conventional synthetic DMARDs (csDMARDs) inadequate…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 2039 • ACR Convergence 2024
Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience
Ozkan Berke Simsek¹, Ali Ayla² and Serdal Ugurlu³, ¹Istanbul University-Cerrahpasa, Istanbul, ²UTHealth Houston Division of Rheumatology, Houston, TX, ³Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Canakinumab is one of the most commonly used second-line agents in familial Mediterranean fever (FMF) after treatment failure or discontinuation of colchicine treatment. The…
Abstract Number: 2347 • ACR Convergence 2024
Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
Thao Pham¹, Raphaëlle Curmin², BENOIT FLACHAIRE³, Florence Tubach² and Corinne MICELI⁴, ¹Assistance Publique-Hôpitaux de Marseille, Marseille, France, ²Cephepi, Sorbonne Université, INSERM, APHP, Paris, Paris, France, ³Aix Marseille University, Marseille, France, ⁴Université de Paris Cité, APHP, Paris, France
Background/Purpose: Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to…
Abstract Number: 2562 • ACR Convergence 2024
Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases
Sophie Carrabin¹, Margaux Houze², Charlotte Jauffret³, Thomas Bardin⁴, Hang Korng Ea⁴, Frédéric Lioté⁴, Pascal Richette⁵, Tristan Pascart² and Augustin Latourte⁶, ¹Hôpital Lariboisière APHP.Nord, Paris, Paris, France, ²Lille Catholic University, Lille, France, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Hôpital Lariboisière APHP.Nord, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶AP-HP, Paris, France
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a heterogeneous disease that can manifest as acute or chronic arthritis. Treatment options for chronic forms of the…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0665 • ACR Convergence 2024
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
Nicolai Leuchten¹, Ioannis Parodis², Ralph Brinks³ and Martin Aringer¹, ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ³University Witten/Herdecke, Witten, Germany
Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
Abstract Number: 0980 • ACR Convergence 2024
Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort
Jiayi Zheng¹, Nevena Barjaktarovic² and Liangjing lu³, ¹Washington University School of Medicine, St. Louis, MO, ²The Wright Center for Community Health, South Abington Township, PA, ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked…
Abstract Number: 1352 • ACR Convergence 2024
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems
Gregory McDermott¹, Xin Xiong², Rachel Knevel³, Jing Cui⁴, Mary Jeffway⁴, Vidul Panickan⁵, Andrew Cagan⁴, Rahul Sangar⁶, Daniel Posner⁶, Lauren Costa⁶, Rachael Matty⁶, Elizabeth Karlson⁴, Yuk-Lam Ho⁶, Kelly Cho⁶, Rui Duan², Tianxi Cai² and Katherine Liao⁴, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA, ⁶U.S. Department of Veterans Affairs, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Anthony Todd⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Jenna Parrett⁵, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel Medsci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…
Abstract Number: 1698 • ACR Convergence 2024
Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Baptiste Chevet¹, Aghiles Souki², nowak emmanuel², Guillermo CARVAJAL ALEGRIA³, Emmanuelle Dernis⁴, Christophe Richez⁵, Marie-Elise Truchetet⁶, DANIEL WENDLING⁷, ERIC TOUSSIROT⁸, aleth Perdriger⁹, Jacques-Eric Gottenberg¹⁰, Renaud FELTEN¹¹, Bruno Fautrel¹², laurent chiche¹³, Anne Walliser-Lohse¹⁴, Pascal Hilliquin¹⁵, Catherine Le Henaff¹⁶, Benjamin Dervieux¹⁷, Guillaume Direz¹⁸, Isabelle Valckenaere¹⁹, Divi Cornec²⁰, Dewi Guellec²¹, Thierry Marhadou²², Alain SARAUX²³ and Valerie Devauchelle²⁴, ¹University Hospital of Brest, Brest, France, ²Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ³CHRU de Tours, Tours, France, ⁴CH LE MANS, LE MANS, Pays de la Loire, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷University Hospital, Besançon, France, ⁸university hospital of BESANCON, besancon, France, ⁹Rennes University, Rennes, France, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Hopitaux Universitaires de Strasbourg, STRASBOURG, France, ¹²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ¹³hopital europeen, marseille, France, ¹⁴Hopital Nord Franche-Comté, BELFORT, France, ¹⁵Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France, ¹⁶Hopital de Morlaix, Morlaix, France, ¹⁷CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁸Hôpital du Mans, Le Mans, France, ¹⁹CHU de Nancy, Nancy, France, ²⁰Service de Rhumatologie, CHU de Brest, Brest, France, ²¹CHU de Brest, Brest, France, ²²CHU Cavale Blanche, Brest, France, ²³CHU Brest, Brest, France, ²⁴UBO, Brest, France
Background/Purpose: The SEMAPHORE trial1 was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease…
Abstract Number: 2040 • ACR Convergence 2024
Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice
Martin Michaud¹, Laurent Sailler², Mélanie LEMEU³, Brice CASTEL⁴, Fabienne Vacheret⁵, Laurent Prudhomme⁶ and Grégory Pugnet⁷, ¹Clinique Saint Exupery, Toulouse, France, ²CHU Toulouse, Toulouse, France, ³CH Albi, Albi, France, ⁴CH TARBES, Tarbes, France, ⁵CH Perpignan, Perpignan, France, ⁶CH Castres, Castres, France, ⁷Toulouse Rangueil University Hospital, Toulouse, France
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory syndrome marked by recurrent pericardial inflammation after an initial episode of acute pericarditis. Standard treatment involves…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].